<DOC>
	<DOCNO>NCT00492557</DOCNO>
	<brief_summary>The 13-valent pneumococcal conjugate vaccine ( 13vPnC ) develop adults prevent pneumococcal disease meningitis ( inflammation brain lining ) , septicemia ( blood poisoning ) , pneumonia ( inflammation lung ) . As trivalent influenza vaccine ( TIV ) frequently give adult , important show vaccine safely give together without affect immune response ( body 's ability protect disease ) .</brief_summary>
	<brief_title>Study Evaluating Safety Immunogenicity 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine Adults</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Generally healthy male female adult 65 year age old . Available duration trial approximately 2 month . No previous vaccination pneumococcal vaccine . No history severe adverse reaction associate vaccine . No allergy egg protein ( egg egg product ) chicken protein .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Pneumococcal Disease</keyword>
	<keyword>Pneumococcal Conjugate Vaccine</keyword>
</DOC>